Petrolatum

Summary

Petrolatum (CHEMBL2108555) is a phase-3 clinical-stage unknown; indicated across 9 conditions including burn and actinic keratosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 9 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108555
Name	Petrolatum
Type	Unknown
Max phase	3

Also known as: Petrolatum, PETROLATUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
burn	3	MONDO:0043519	EFO:0009516
actinic keratosis	2	MONDO:0005173	EFO:0002496
staphylococcus aureus infection	2	MONDO:0005545	EFO:0005681
psoriasis	2	MONDO:0005083	EFO:0000676
sunburn	2	MONDO:0005326	EFO:0003958
injury	1	MONDO:0021178	EFO:0000546
disease of the tendon	1	MONDO:0100010	EFO:1001434
radiodermatitis	0	MONDO:0043771	MONDO:0043771

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
Not specified	5
PHASE2	4
PHASE4	3
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00179959	PHASE4	COMPLETED	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
NCT01388517	PHASE4	COMPLETED	Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba
NCT03799484	PHASE4	COMPLETED	Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment
NCT04071106	PHASE2/PHASE3	UNKNOWN	Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial
NCT04951349	PHASE2	COMPLETED	Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
NCT05254925	PHASE2	COMPLETED	Phototoxicity Potential of 6% Bemotrizinol
NCT05260359	PHASE2	COMPLETED	Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
NCT05314127	PHASE2	UNKNOWN	Efficacy of Tazarotene in Treatment of Verruca Plana
NCT01935869	PHASE1	COMPLETED	Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100
NCT02355639	PHASE1	COMPLETED	A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
NCT07183423	Not specified	RECRUITING	Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
NCT02543034	Not specified	COMPLETED	Compare of Petrolatum Gauze, Allevyn, and New Dressing, Betafoam® in the Management of Split-Thickness Skin Graft Donor Site
NCT03625167	Not specified	COMPLETED	Effect of a Basic Skin Care Product on the Structural Strength of the Skin
NCT04169438	Not specified	COMPLETED	Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions
NCT05353374	Not specified	COMPLETED	Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).